Binding LOI for proposed acquisition of Galidesivir
Filed with ASX · · 3 pages · English
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- ISLA-101 Phase 2a/b clinical trial progresses
- Non-binding term sheet signed with BioCryst
- Investor Presentation
- New data leads to proposed ISLA-101 Phase 2 efficiencies
- Grant funding to directly support Phase 2a trial
Later from Island Pharmaceuticals
- Phase 2a PROTECT clinical trial dosed & Investor webinar
- Island completes $3.5m Placement
- Clinical trial progress update
- Receipt of R&D tax refund for FY2024
- ISLA-101 shows anti-dengue activity in Phase 2a readout
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals